NCT03943537View on ClinicalTrials.gov

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

February 23, 2024

Study Completion Date

February 23, 2024

Conditions
PsychosisSchizophreniaSchizo Affective DisorderBipolar I Disorder
Interventions
DRUG

Intranasal Insulin

40 units Novolin R administered intranasally using ViaNase device.

Trial Locations (1)

02478

McLean Hospital, Belmont

All Listed Sponsors
lead

Mclean Hospital

OTHER

NCT03943537 - Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders | Biotech Hunter | Biotech Hunter